This ninth issue of DDup (Drug Discovery Update) will provide an overview of our unique and innovative iPSC-based drug discovery programs with a focus on Retinal Disease which we have developed in collaboration with our colleagues from the Centre for Regenerative Therapies TU Dresden. This issue is the second part
of our DDup iPSC series, the first partwas published in May 2019, dedicated to Evotec’s leading iPSC platform.

Evotec has started numerous iPSC-based drug discovery projects in the past few years and has steadily advanced the development of its iPSC platform, by establishing the largest high-quality iPSC bank and diverse human disease models for high-throughput screening. Our ambition is to advance selected programs
with partners dedicated to iPSC-based drug discovery.

Download the drug discovery update to learn more about iPSC-Based Retinal Disease.